Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
Identifieur interne : 000818 ( Main/Corpus ); précédent : 000817; suivant : 000819Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
Auteurs : Yüksel Ürün ; Syed A. Hussain ; Ziad Bakouny ; Daniel Castellano ; Saadettin K L Çkap ; Gilberto Morgan ; Rana R. Mckay ; Kevin Pels ; Andrew Schmidt ; Deborah B. Doroshow ; Fábio Schütz ; Laurence Albiges ; Gilberto Lopes ; James W F. Catto ; Solange Peters ; Toni K. ChoueiriSource :
- JCO global oncology [ 2687-8941 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Betacoronavirus (pathogenicity), Clinical Decision-Making (MeSH), Coronavirus Infections (epidemiology), Coronavirus Infections (prevention & control), Coronavirus Infections (transmission), Coronavirus Infections (virology), Female (MeSH), Humans (MeSH), Infection Control (methods), Infection Control (standards), Infection Control (statistics & numerical data), Infectious Disease Transmission, Patient-to-Professional (prevention & control), Infectious Disease Transmission, Professional-to-Patient (prevention & control), Male (MeSH), Medical Oncology (methods), Medical Oncology (standards), Medical Oncology (statistics & numerical data), Middle Aged (MeSH), Neoplasms (diagnosis), Neoplasms (therapy), Oncologists (statistics & numerical data), Pandemics (prevention & control), Personal Protective Equipment (standards), Personal Protective Equipment (statistics & numerical data), Pneumonia, Viral (epidemiology), Pneumonia, Viral (prevention & control), Pneumonia, Viral (transmission), Pneumonia, Viral (virology), Practice Patterns, Physicians' (standards), Practice Patterns, Physicians' (statistics & numerical data), Surveys and Questionnaires (statistics & numerical data), Telemedicine (statistics & numerical data).
- MESH :
- diagnosis : Neoplasms.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- methods : Infection Control, Medical Oncology.
- pathogenicity : Betacoronavirus.
- prevention & control : Coronavirus Infections, Infectious Disease Transmission, Patient-to-Professional, Infectious Disease Transmission, Professional-to-Patient, Pandemics, Pneumonia, Viral.
- standards : Infection Control, Medical Oncology, Personal Protective Equipment, Practice Patterns, Physicians'.
- statistics & numerical data : Infection Control, Medical Oncology, Oncologists, Personal Protective Equipment, Practice Patterns, Physicians', Surveys and Questionnaires, Telemedicine.
- therapy : Neoplasms.
- transmission : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Adult, Aged, Clinical Decision-Making, Female, Humans, Male, Middle Aged.
Abstract
PURPOSE
To understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic.
METHODS
An online survey was conducted between March 24 and April 29, 2020.
RESULTS
A total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68 years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters, was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% reported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in all patients. The most significant factors influencing an oncologist's decision making regarding choice of systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants. The vast majority of participants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors, and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected, most of the participants stated that they would be more hesitant to recommend second- or third-line therapies in metastatic disease.
CONCLUSION
Decision making by oncologists has been significantly influenced by the ongoing COVID-19 pandemic.
DOI: 10.1200/GO.20.00300
PubMed: 32755479
PubMed Central: PMC7456315
Links to Exploration step
pubmed:32755479Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.</title><author><name sortKey="Urun, Yuksel" sort="Urun, Yuksel" uniqKey="Urun Y" first="Yüksel" last="Ürün">Yüksel Ürün</name><affiliation><nlm:affiliation>Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Ankara University Cancer Research Institute, Ankara, Turkey.</nlm:affiliation></affiliation></author><author><name sortKey="Hussain, Syed A" sort="Hussain, Syed A" uniqKey="Hussain S" first="Syed A" last="Hussain">Syed A. Hussain</name><affiliation><nlm:affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Bakouny, Ziad" sort="Bakouny, Ziad" uniqKey="Bakouny Z" first="Ziad" last="Bakouny">Ziad Bakouny</name><affiliation><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Castellano, Daniel" sort="Castellano, Daniel" uniqKey="Castellano D" first="Daniel" last="Castellano">Daniel Castellano</name><affiliation><nlm:affiliation>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="K L Ckap, Saadettin" sort="K L Ckap, Saadettin" uniqKey="K L Ckap S" first="Saadettin" last="K L Çkap">Saadettin K L Çkap</name><affiliation><nlm:affiliation>Hacettepe University Cancer Institute, Ankara, Turkey.</nlm:affiliation></affiliation></author><author><name sortKey="Morgan, Gilberto" sort="Morgan, Gilberto" uniqKey="Morgan G" first="Gilberto" last="Morgan">Gilberto Morgan</name><affiliation><nlm:affiliation>Department of Medical and Radiation Oncology, Skåne University Hospital, Lund, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Mckay, Rana R" sort="Mckay, Rana R" uniqKey="Mckay R" first="Rana R" last="Mckay">Rana R. Mckay</name><affiliation><nlm:affiliation>Moores Cancer Center, University of California San Diego, La Jolla, CA.</nlm:affiliation></affiliation></author><author><name sortKey="Pels, Kevin" sort="Pels, Kevin" uniqKey="Pels K" first="Kevin" last="Pels">Kevin Pels</name><affiliation><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Schmidt, Andrew" sort="Schmidt, Andrew" uniqKey="Schmidt A" first="Andrew" last="Schmidt">Andrew Schmidt</name><affiliation><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Doroshow, Deborah B" sort="Doroshow, Deborah B" uniqKey="Doroshow D" first="Deborah B" last="Doroshow">Deborah B. Doroshow</name><affiliation><nlm:affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.</nlm:affiliation></affiliation></author><author><name sortKey="Schutz, Fabio" sort="Schutz, Fabio" uniqKey="Schutz F" first="Fábio" last="Schütz">Fábio Schütz</name><affiliation><nlm:affiliation>Clinical Oncology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Albiges, Laurence" sort="Albiges, Laurence" uniqKey="Albiges L" first="Laurence" last="Albiges">Laurence Albiges</name><affiliation><nlm:affiliation>Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lopes, Gilberto" sort="Lopes, Gilberto" uniqKey="Lopes G" first="Gilberto" last="Lopes">Gilberto Lopes</name><affiliation><nlm:affiliation>Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.</nlm:affiliation></affiliation></author><author><name sortKey="Catto, James W F" sort="Catto, James W F" uniqKey="Catto J" first="James W F" last="Catto">James W F. Catto</name><affiliation><nlm:affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Peters, Solange" sort="Peters, Solange" uniqKey="Peters S" first="Solange" last="Peters">Solange Peters</name><affiliation><nlm:affiliation>Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Choueiri, Toni K" sort="Choueiri, Toni K" uniqKey="Choueiri T" first="Toni K" last="Choueiri">Toni K. Choueiri</name><affiliation><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32755479</idno><idno type="pmid">32755479</idno><idno type="doi">10.1200/GO.20.00300</idno><idno type="pmc">PMC7456315</idno><idno type="wicri:Area/Main/Corpus">000818</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000818</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.</title><author><name sortKey="Urun, Yuksel" sort="Urun, Yuksel" uniqKey="Urun Y" first="Yüksel" last="Ürün">Yüksel Ürün</name><affiliation><nlm:affiliation>Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Ankara University Cancer Research Institute, Ankara, Turkey.</nlm:affiliation></affiliation></author><author><name sortKey="Hussain, Syed A" sort="Hussain, Syed A" uniqKey="Hussain S" first="Syed A" last="Hussain">Syed A. Hussain</name><affiliation><nlm:affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Bakouny, Ziad" sort="Bakouny, Ziad" uniqKey="Bakouny Z" first="Ziad" last="Bakouny">Ziad Bakouny</name><affiliation><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Castellano, Daniel" sort="Castellano, Daniel" uniqKey="Castellano D" first="Daniel" last="Castellano">Daniel Castellano</name><affiliation><nlm:affiliation>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="K L Ckap, Saadettin" sort="K L Ckap, Saadettin" uniqKey="K L Ckap S" first="Saadettin" last="K L Çkap">Saadettin K L Çkap</name><affiliation><nlm:affiliation>Hacettepe University Cancer Institute, Ankara, Turkey.</nlm:affiliation></affiliation></author><author><name sortKey="Morgan, Gilberto" sort="Morgan, Gilberto" uniqKey="Morgan G" first="Gilberto" last="Morgan">Gilberto Morgan</name><affiliation><nlm:affiliation>Department of Medical and Radiation Oncology, Skåne University Hospital, Lund, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Mckay, Rana R" sort="Mckay, Rana R" uniqKey="Mckay R" first="Rana R" last="Mckay">Rana R. Mckay</name><affiliation><nlm:affiliation>Moores Cancer Center, University of California San Diego, La Jolla, CA.</nlm:affiliation></affiliation></author><author><name sortKey="Pels, Kevin" sort="Pels, Kevin" uniqKey="Pels K" first="Kevin" last="Pels">Kevin Pels</name><affiliation><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Schmidt, Andrew" sort="Schmidt, Andrew" uniqKey="Schmidt A" first="Andrew" last="Schmidt">Andrew Schmidt</name><affiliation><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Doroshow, Deborah B" sort="Doroshow, Deborah B" uniqKey="Doroshow D" first="Deborah B" last="Doroshow">Deborah B. Doroshow</name><affiliation><nlm:affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.</nlm:affiliation></affiliation></author><author><name sortKey="Schutz, Fabio" sort="Schutz, Fabio" uniqKey="Schutz F" first="Fábio" last="Schütz">Fábio Schütz</name><affiliation><nlm:affiliation>Clinical Oncology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Albiges, Laurence" sort="Albiges, Laurence" uniqKey="Albiges L" first="Laurence" last="Albiges">Laurence Albiges</name><affiliation><nlm:affiliation>Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lopes, Gilberto" sort="Lopes, Gilberto" uniqKey="Lopes G" first="Gilberto" last="Lopes">Gilberto Lopes</name><affiliation><nlm:affiliation>Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.</nlm:affiliation></affiliation></author><author><name sortKey="Catto, James W F" sort="Catto, James W F" uniqKey="Catto J" first="James W F" last="Catto">James W F. Catto</name><affiliation><nlm:affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Peters, Solange" sort="Peters, Solange" uniqKey="Peters S" first="Solange" last="Peters">Solange Peters</name><affiliation><nlm:affiliation>Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Choueiri, Toni K" sort="Choueiri, Toni K" uniqKey="Choueiri T" first="Toni K" last="Choueiri">Toni K. Choueiri</name><affiliation><nlm:affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">JCO global oncology</title><idno type="eISSN">2687-8941</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Betacoronavirus (pathogenicity)</term><term>Clinical Decision-Making (MeSH)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (transmission)</term><term>Coronavirus Infections (virology)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Infection Control (methods)</term><term>Infection Control (standards)</term><term>Infection Control (statistics & numerical data)</term><term>Infectious Disease Transmission, Patient-to-Professional (prevention & control)</term><term>Infectious Disease Transmission, Professional-to-Patient (prevention & control)</term><term>Male (MeSH)</term><term>Medical Oncology (methods)</term><term>Medical Oncology (standards)</term><term>Medical Oncology (statistics & numerical data)</term><term>Middle Aged (MeSH)</term><term>Neoplasms (diagnosis)</term><term>Neoplasms (therapy)</term><term>Oncologists (statistics & numerical data)</term><term>Pandemics (prevention & control)</term><term>Personal Protective Equipment (standards)</term><term>Personal Protective Equipment (statistics & numerical data)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (prevention & control)</term><term>Pneumonia, Viral (transmission)</term><term>Pneumonia, Viral (virology)</term><term>Practice Patterns, Physicians' (standards)</term><term>Practice Patterns, Physicians' (statistics & numerical data)</term><term>Surveys and Questionnaires (statistics & numerical data)</term><term>Telemedicine (statistics & numerical data)</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Infection Control</term><term>Medical Oncology</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Infectious Disease Transmission, Patient-to-Professional</term><term>Infectious Disease Transmission, Professional-to-Patient</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Infection Control</term><term>Medical Oncology</term><term>Personal Protective Equipment</term><term>Practice Patterns, Physicians'</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Infection Control</term><term>Medical Oncology</term><term>Oncologists</term><term>Personal Protective Equipment</term><term>Practice Patterns, Physicians'</term><term>Surveys and Questionnaires</term><term>Telemedicine</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Clinical Decision-Making</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>PURPOSE</b></p><p>To understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>An online survey was conducted between March 24 and April 29, 2020.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68 years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters, was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% reported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in all patients. The most significant factors influencing an oncologist's decision making regarding choice of systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants. The vast majority of participants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors, and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected, most of the participants stated that they would be more hesitant to recommend second- or third-line therapies in metastatic disease.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Decision making by oncologists has been significantly influenced by the ongoing COVID-19 pandemic.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32755479</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2020</Year><Month>08</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.</ArticleTitle><Pagination><MedlinePgn>1248-1257</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO.20.00300</ELocationID><Abstract><AbstractText Label="PURPOSE">To understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic.</AbstractText><AbstractText Label="METHODS">An online survey was conducted between March 24 and April 29, 2020.</AbstractText><AbstractText Label="RESULTS">A total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68 years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters, was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% reported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in all patients. The most significant factors influencing an oncologist's decision making regarding choice of systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants. The vast majority of participants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors, and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected, most of the participants stated that they would be more hesitant to recommend second- or third-line therapies in metastatic disease.</AbstractText><AbstractText Label="CONCLUSION">Decision making by oncologists has been significantly influenced by the ongoing COVID-19 pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ürün</LastName><ForeName>Yüksel</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ankara University Cancer Research Institute, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Syed A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakouny</LastName><ForeName>Ziad</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellano</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kılıçkap</LastName><ForeName>Saadettin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hacettepe University Cancer Institute, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Gilberto</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical and Radiation Oncology, Skåne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mckay</LastName><ForeName>Rana R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Moores Cancer Center, University of California San Diego, La Jolla, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pels</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doroshow</LastName><ForeName>Deborah B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schütz</LastName><ForeName>Fábio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical Oncology Department, BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albiges</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Gilberto</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catto</LastName><ForeName>James W F</ForeName><Initials>JWF</Initials><AffiliationInfo><Affiliation>Academic Unit of Oncology, University of Sheffield, Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Solange</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choueiri</LastName><ForeName>Toni K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066491" MajorTopicYN="Y">Clinical Decision-Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017053" MajorTopicYN="N">Infection Control</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017758" MajorTopicYN="N">Infectious Disease Transmission, Patient-to-Professional</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017757" MajorTopicYN="N">Infectious Disease Transmission, Professional-to-Patient</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008495" MajorTopicYN="N">Medical Oncology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072103" MajorTopicYN="N">Oncologists</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067393" MajorTopicYN="N">Personal Protective Equipment</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017216" MajorTopicYN="N">Telemedicine</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32755479</ArticleId><ArticleId IdType="doi">10.1200/GO.20.00300</ArticleId><ArticleId IdType="pmc">PMC7456315</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cancer Discov. 2020 Jun;10(6):783-791</Citation><ArticleIdList><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation><ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 May 26;323(20):2005-2006</Citation><ArticleIdList><ArticleId IdType="pubmed">32282023</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Apr 9;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32270882</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Oncol. 2020 Jul 1;6(7):1108-1110</Citation><ArticleIdList><ArticleId IdType="pubmed">32211820</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 May 1;368(6490):489-493</Citation><ArticleIdList><ArticleId IdType="pubmed">32179701</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 4;382(23):e82</Citation><ArticleIdList><ArticleId IdType="pubmed">32240581</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1679-1681</Citation><ArticleIdList><ArticleId IdType="pubmed">32160451</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2020 Mar;21(3):335-337</Citation><ArticleIdList><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2020 Apr 1;3(4):e205619</Citation><ArticleIdList><ArticleId IdType="pubmed">32275319</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):970-971</Citation><ArticleIdList><ArticleId IdType="pubmed">32003551</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2020 Jul;78(1):124-126</Citation><ArticleIdList><ArticleId IdType="pubmed">32349934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2020 Jul;31(7):894-901</Citation><ArticleIdList><ArticleId IdType="pubmed">32224151</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Haematol. 2020 Jun;7(6):e432-e435</Citation><ArticleIdList><ArticleId IdType="pubmed">32339482</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Oncol. 2016 Oct 1;2(10):1346-1353</Citation><ArticleIdList><ArticleId IdType="pubmed">27367787</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2020 May;21(5):634-636</Citation><ArticleIdList><ArticleId IdType="pubmed">32359487</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2020 Jul 1;38(19):2201-2205</Citation><ArticleIdList><ArticleId IdType="pubmed">32343643</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 May 26;323(20):2052-2059</Citation><ArticleIdList><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2020 Aug;31(8):1065-1074</Citation><ArticleIdList><ArticleId IdType="pubmed">32442581</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1858-1859</Citation><ArticleIdList><ArticleId IdType="pubmed">32251568</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2020 Jun;77(6):663-666</Citation><ArticleIdList><ArticleId IdType="pubmed">32279903</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2020 Jun;77(6):667-668</Citation><ArticleIdList><ArticleId IdType="pubmed">32312544</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2020 Aug;31(8):1040-1045</Citation><ArticleIdList><ArticleId IdType="pubmed">32387456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2020 May;21(5):619-621</Citation><ArticleIdList><ArticleId IdType="pubmed">32220659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Discov. 2020 Jul;10(7):935-941</Citation><ArticleIdList><ArticleId IdType="pubmed">32357994</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 May;26(5):665-671</Citation><ArticleIdList><ArticleId IdType="pubmed">32405058</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2020 Jul;78(1):29-42</Citation><ArticleIdList><ArticleId IdType="pubmed">32414626</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Discov. 2020 Aug;10(8):1121-1128</Citation><ArticleIdList><ArticleId IdType="pubmed">32398243</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Cancer. 2020 Apr 21;:1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">32346676</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunotherapy. 2020 Apr;12(5):269-273</Citation><ArticleIdList><ArticleId IdType="pubmed">32212881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>JCO Glob Oncol. 2020 Apr;6:557-559</Citation><ArticleIdList><ArticleId IdType="pubmed">32250659</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2020 Apr 16;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32301491</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2020 Jul;78(1):e27-e35</Citation><ArticleIdList><ArticleId IdType="pubmed">32345523</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2020 Jun;21(6):748-750</Citation><ArticleIdList><ArticleId IdType="pubmed">32359404</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Urol. 2020 Jul;78(1):21-28</Citation><ArticleIdList><ArticleId IdType="pubmed">32376137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2020 Aug;31(8):1088-1089</Citation><ArticleIdList><ArticleId IdType="pubmed">32330541</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2020 Jun;21(6):750-751</Citation><ArticleIdList><ArticleId IdType="pubmed">32359403</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Cell. 2020 Jun 8;37(6):738-741</Citation><ArticleIdList><ArticleId IdType="pubmed">32454025</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncologist. 2020 Jun;25(6):463-467</Citation><ArticleIdList><ArticleId IdType="pubmed">32298029</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000818 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000818 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32755479
|texte= Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32755479" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |